ReviewTrends in cardiovascular medicine2017
Tissue-engineered vascular grafts for congenital cardiac disease: Clinical experience and current status.
Review in Trends in cardiovascular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 65 citations in OpenAlex.
- Ex vivo endothelialized cECM-enriched core-shell fibrous vascular graft promotes rapid regenerative remodeling in vivo.Bioactive materials · 2026Article
- Induced Pluripotent Stem Cell-Derived Small-Diameter Vascular Grafts: Scaffold Design, Immune Engineering, and Clinical Translation.Journal of cellular physiology · 2026Review
- Advancements in pediatric tissue engineering: scaffold-based and cell-driven approaches.Cell and tissue banking · 2026Review
- An Automated Modular Platform for Vascular Graft Assessment via Coronary-like Flow-Induced Stimulation.Bioengineering (Basel, Switzerland) · 2026Article
- Recellularization of decellularized vascular grafts via aligned seeding of endothelial cells derived from human iPS cells.Scientific reports · 2025Article
- Recent Advances in Hydrogel-Based 3D Bioprinting and Its Potential Application in the Treatment of Congenital Heart Disease.Biomolecules · 2024Review
- Bioengineering Human Tissues and the Future of Vascular Replacement.Circulation research · 2022Review
- Structural Aspects of Electrospun Scaffolds Intended for Prosthetics of Blood Vessels.Polymers · 2022Review
- Vascular implants - new aspects for in situ tissue engineering.Engineering in life sciences · 2022Review
- Tissue engineered in-vitro vascular patch fabrication using hybrid 3D printing and electrospinning.Materials today. Bio · 2022Article
- Strategies to counteract adverse remodeling of vascular graft: A 3D view of current graft innovations.Frontiers in bioengineering and biotechnology · 2022Review
- Tissue engineered vascular grafts transform into autologous neovessels capable of native function and growth.Communications medicine · 2022Article
- Hemodynamic performance of tissue-engineered vascular grafts in Fontan patients.NPJ Regenerative medicine · 2021Article
- Assessment of Electrospun Pellethane-Based Scaffolds for Vascular Tissue Engineering.Materials (Basel, Switzerland) · 2021Article
- Tissue-engineered vascular microphysiological platform to study immune modulation of xenograft rejection.Science advances · 2021Article
- The Real Need for Regenerative Medicine in the Future of Congenital Heart Disease Treatment.Biomedicines · 2021Review
- Mechanically tuned vascular graft demonstrates rapid endothelialization and integration into the porcine iliac artery wall.Acta biomaterialia · 2021Article
- Tunable Blood Shunt for Neonates With Complex Congenital Heart Defects.Frontiers in bioengineering and biotechnology · 2021Article
- Spontaneous reversal of stenosis in tissue-engineered vascular grafts.Science translational medicine · 2020Article
- Evaluation of personalized right ventricle to pulmonary artery conduits using in silico design and computational analysis of flow.JTCVS open · 2020Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Congenital heart disease is a leading cause of death in the newborn period, and man-made grafts currently used for reconstruction are associated with multiple complications. Tissue engineering can provide an alternative source of vascular tissue in congenital cardiac surgery. Clinical trials have been successful overall, but the most frequent complication is graft stenosis. Recent studies in animal models have indicated the important role of the recipient׳s immune response in neotissue formation, and that modulating the immune response can reduce the incidence of stenosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.